Bristol-Myers Squibb and Pfizer report positive real-world data for Eliquis

Bristol-Myers Squibb and Pfizer have reported new data from a real-world study that reinforces the benefits of the anticoagulant therapy Eliquis.

The new analysis looked at outcomes among different direct oral anticoagulants, including Eliquis, rivaroxaban and dabigatran, in what was the largest study of its kind to date.

Eliquis use was associated with significantly lower rates of stroke, systemic embolism and major bleeding compared to alternative treatment options, with data from the study encompassing more than half of the US population.

Dr Steven Deitelzweig, system department chair of hospital medicine at the Ochsner Medical Center in New Orleans, said: "Being able to see patient claims from different data sets with good representation across the country may help decision making in clinical practice."

This comes as part of a wider study programme that Pfizer and Bristol-Myers Squibb are conducting to generate additional evidence from routine clinical practice settings, in order to further inform healthcare decision-makers, including healthcare providers and payers.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.